SINEW Business Summary

Sinew Pharma Inc. (6634.TWO) is a clinical-stage biopharmaceutical company headquartered in Taiwan that operates primarily through a high-value licensing and research-driven revenue model. The company generates income through strategic partnerships, milestone payments, and technology transfers centered on its proprietary drug development platforms, which focus on metabolic and liver-related pathologies. Its primary business segments are divided into three therapeutic pillars: metabolic dysfunction-associated steatohepatitis (MASH/NASH) treatments, non-addictive and hepatotoxicity-free analgesics, and liver-protective antidotes. Key pipeline candidates include SNP-610 and SNP-630 for MASH, and SNP-810, a novel acetaminophen formulation designed to eliminate liver toxicity. Within the global biotechnology landscape, Sinew Pharma competes with major MASH-focused firms such as Madrigal Pharmaceuticals and Akero Therapeutics, as well as regional innovators like Senhwa Biosciences. The company distinguishes itself by leveraging pharmacokinetic-driven systems to address critical safety gaps in existing standard-of-care treatments for liver disease and chronic pain. The leadership team is anchored by Chairman and CEO Dr. Kai-Min Chu, a prominent medical professional who previously served as the Director of the Clinical Research Center and Director of Cardiology at the Tri-Service General Hospital. Supporting the executive suite are Chief Operating Officer Dr. Cheng-Huei Hsiong, an expert in biomedical engineering and former research fellow at National Defense Medical School, and Chief Technology Officer Dr. Hsin-Tien Ho, who brings extensive experience in life sciences and pharmaceutical R&D. The company’s strategic direction is further bolstered by a prestigious Scientific Advisory Board featuring Dr. Wei-Chao Chen, the former President of National Taiwan University, and Dr. Oliver Yoa-Pu Hu, a renowned pharmacologist credited with inventing Taiwan’s first non-addictive severe pain reliever. This deep academic and clinical pedigree is a core asset for the company as it navigates complex Phase II and Phase III global clinical trials.